Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
biphasic human insulin 30 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Formulation A | EXPERIMENTAL | - |
| Formulation B | ACTIVE_COMPARATOR | - |
| NN2000 | EXPERIMENTAL | - |
| NN-X14 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| biphasic human insulin 30 | DRUG | Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits |
Inclusion Criteria: * Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator * Body Mass Index (BMI) between 18.0 and 27.0 kg/m\^2, inclusive * Non-smoker, defined as no nicotine consumption for at least one year * Fasting plasma gluco...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
Biphasic human insulin 30 is used for diabetes. It is a small molecule being developed by Novo Nordisk A/S. The drug is currently in Phase 1 clinical development, with two completed trials that included healthy subjects and individuals with diabetes.
Novo Nordisk A/S (ticker: NVO) is developing biphasic human insulin 30. The company is conducting clinical trials for this diabetes treatment, which is currently in Phase 1 development.
Biphasic human insulin 30 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and has completed two Phase 1 trials. The trials were randomized, double-blind, and active-controlled, with a total enrollment of 79 participants.
Biphasic human insulin 30 has two completed Phase 1 trials: NCT01486888, a bioequivalence study of two Mixtard 30 formulations in healthy subjects in Germany, and NCT01620450, comparing insulin aspart produced by current and NN2000 processes in healthy Japanese males.
Biphasic human insulin 30 is associated with Mixtard 30, as one clinical trial (NCT01486888) evaluated the bioequivalence of two Mixtard 30 formulations. The drug is being developed by Novo Nordisk for diabetes and is currently in Phase 1.